Joshua Henshaw

811 total citations
21 papers, 464 citations indexed

About

Joshua Henshaw is a scholar working on Molecular Biology, Rheumatology and Epidemiology. According to data from OpenAlex, Joshua Henshaw has authored 21 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Rheumatology and 4 papers in Epidemiology. Recurrent topics in Joshua Henshaw's work include Hepatitis C virus research (4 papers), Virus-based gene therapy research (3 papers) and Lysosomal Storage Disorders Research (3 papers). Joshua Henshaw is often cited by papers focused on Hepatitis C virus research (4 papers), Virus-based gene therapy research (3 papers) and Lysosomal Storage Disorders Research (3 papers). Joshua Henshaw collaborates with scholars based in United States, France and Germany. Joshua Henshaw's co-authors include Bambang S. Adiwijaya, Varun Garg, Kenneth E. Sherman, Douglas T. Dieterich, Raymond A. Rubin, Nathalie Adda, Mohammad Bsharat, Vincent Soriano, Pierre‐Marie Girard and Mark Sulkowski and has published in prestigious journals such as Annals of Internal Medicine, Journal of Hepatology and PLoS Computational Biology.

In The Last Decade

Joshua Henshaw

20 papers receiving 452 citations

Peers

Countries citing papers authored by Joshua Henshaw

Since Specialization

Citations

This map shows the geographic impact of Joshua Henshaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua Henshaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua Henshaw more than expected).

Fields of papers citing papers by Joshua Henshaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua Henshaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua Henshaw. The network helps show where Joshua Henshaw may publish in the future.

Co-authorship network of co-authors of Joshua Henshaw

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua Henshaw. A scholar is included among the top collaborators of Joshua Henshaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua Henshaw. Joshua Henshaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	BMN 351-Induced Exon Skipping and Dystrophin Expression in Skeletal and Cardiac Muscle Lead to Preservation of Motor Function in a Mouse Model of Exon 51 Skip-Amenable Duchenne Muscular Dystrophy 2025 ·Nucleic Acid Therapeutics ·(unknown), (unknown), Joshua Henshaw, Kevin Larimore, Jukka Puoliväli, (unknown), (unknown), Stephen Brennan, (unknown), Monika Abedin Sigg, Charles O’Neill	2
2	Targeting a Novel Site in Exon 51 with Antisense Oligonucleotides Induces Enhanced Exon Skipping in a Mouse Model of Duchenne Muscular Dystrophy 2025 ·Nucleic Acid Therapeutics ·(unknown), (unknown), Joshua Henshaw, Kevin Larimore, Andrew C. Melton, Jukka Puoliväli, (unknown), (unknown), Stephen O. Brennan, (unknown), Monika Abedin Sigg, Brett E. Crawford, (unknown), Steven Froelich, Josh C. Woloszynek, Charles O’Neill	1
3	Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A 2024 ·Molecular Therapy ·(unknown), Tara M. Robinson, (unknown), (unknown), (unknown), (unknown), Kathryn Patton, (unknown), Joshua Henshaw, Suresh Agarwal, Christian Vettermann, Stephen J. Zoog, Soumi Gupta	11
4	Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A 2024 ·Blood Advances ·(unknown), (unknown), (unknown), (unknown), Alisa Bowen, (unknown), Jennifer Holcomb, Tara M. Robinson, Kala Jayaram, Chris B. Russell, Stephen J. Zoog, Christian Vettermann, Joshua Henshaw	2
5	Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys 2023 ·Toxicology Reports ·Jason Pinkstaff, Emma McCullagh, Anita Grover, Andrew C. Melton, Anu Cherukuri, (unknown), (unknown), Mark T. Butt, (unknown), (unknown), (unknown), Robert B. Boyd, Sundeep Chandra, Joshua Henshaw, Charles O’Neill, Eric Zanelli, Joseph Kovalchin	0
6	Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy 2022 ·Gene Therapy ·Carlos Fonck, Cheng Su, (unknown), (unknown), Jaydeep K. Srimani, Joshua Henshaw, (unknown), Sundeep Chandra, Christian Vettermann, Charles O’Neill	5
7	Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer 2021 ·Gene Therapy ·(unknown), (unknown), (unknown), (unknown), Fan Yang, Jennifer Holcomb, Kathryn Patton, (unknown), Nina Mitchell, Wing Yen Wong, Stephen J. Zoog, Benjamin Kim, Joshua Henshaw, Christian Vettermann	3
8	Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia 2021 ·Clinical Pharmacokinetics ·(unknown), (unknown), Kevin Larimore, Anu Cherukuri, (unknown), Kala Jayaram, George Jeha, Elena Fisheleva, Jonathan Day, Alice Huntsman-Labed, Ravi Savarirayan, Melita Irving, Carlos A. Bacino, Julie Hoover‐Fong, Keiichi Ozono, Klaus Mohnike, William R. Wilcox, William A. Horton, Joshua Henshaw	20
9	Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria 2021 ·Clinical and Translational Science ·(unknown), (unknown), Joshua Henshaw, Soumi Gupta, Joy Olbertz, Kevin Larimore, Cary O. Harding, Markus Meriläinen, Roberto T. Zori, Nicola Longo, Barbara K. Burton, Mingjin Li, (unknown), Stephen J. Zoog, Haoling H. Weng, Becky Schweighardt	14
10	Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study 2018 ·Clinical Immunology ·Anu Cherukuri, Heather Cahan, (unknown), (unknown), Peter Slasor, (unknown), Joshua Henshaw, Temitayo Ajayi, (unknown), Charles O’Neill, Becky Schweighardt	25
11	Intravitreal enzyme replacement therapy attenuates retinal disease progression in a canine model of neuronal ceroid lipofuscinosis type 2 (CLN2) 2018 ·Molecular Genetics and Metabolism ·John Sinclair, Rebecca E.H. Whiting, Grace O. Robinson, (unknown), (unknown), Anu Cherukuri, Joshua Henshaw, (unknown), (unknown), (unknown), Martin L. Katz	2
12	Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis 2014 ·Molecular Genetics and Metabolism ·Brian R. Vuillemenot, Derek Kennedy, Jonathan D. Cooper, Andrew M.S. Wong, Sarmi Sri, (unknown), Martin L. Katz, Joan R. Coates, Gayle C. Johnson, (unknown), (unknown), Mark T. Butt, Donald G. Musson, Joshua Henshaw, (unknown), (unknown), Laurie Tsuruda, Charles O’Neill	49
13	Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV 2013 ·Annals of Internal Medicine ·Mark Sulkowski, Kenneth E. Sherman, Douglas T. Dieterich, Mohammad Bsharat, Lisa Mahnke, Jürgen K. Rockstroh, Shahin Gharakhanian, Scott McCallister, Joshua Henshaw, Pierre‐Marie Girard, Bambang S. Adiwijaya, Varun Garg, Raymond A. Rubin, Nathalie Adda, Vincent Soriano	156
14	A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection 2012 ·PLoS Computational Biology ·Bambang S. Adiwijaya, Tara L. Kieffer, Joshua Henshaw, Karen Eisenhauer, Holly Kimko, John Alam, Robert S. Kauffman, Varun Garg	28
15	Telaprevir-Related Dermatitis 2012 ·JAMA Dermatology ·Jean‐Claude Roujeau, Maja Mockenhaupt, Steven R. Tahan, Joshua Henshaw, Emily C. Martin, (unknown), Ben Van Baelen, Leif Bengtsson, Priya Singhal, Robert S. Kauffman, Robert S. Stern	43
16	Telaprevir in combination with peginterferon Alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis 2012 ·Douglas T. Dieterich, Vincent Soriano, Kenneth E. Sherman, Pierre‐Marie Girard, (unknown), Joshua Henshaw, Raymond A. Rubin, Mohammad Bsharat, Nathalie Adda, Mark Sulkowski	16
17	1116 EXPOSURE-RESPONSE RELATIONSHIPS IN TELAPREVIR COMBINATION THERAPY IN TREATMENT-NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS 2012 ·Journal of Hepatology ·Stuart C. Gordon, Andrew J. Muir, Varun Garg, Joshua Henshaw	2
18	Enhancement of electric field-mediated gene delivery through pretreatment of tumors with a hyperosmotic mannitol solution 2010 ·Cancer Gene Therapy ·Joshua Henshaw, (unknown), Fan Yuan	10
19	Relaxin treatment of solid tumors: effects on electric field–mediated gene delivery 2008 ·Molecular Cancer Therapeutics ·Joshua Henshaw, (unknown), Fan Yuan	13
20	Nano-biosensor development for bacterial detection during human kidney infection: Use of glycoconjugate-specific antibody-bound gold NanoWire arrays (GNWA) 2004 ·Glycoconjugate Journal ·Manju Basu, (unknown), Joshua Henshaw, Juan Jiang, (unknown), Clare V. LeFave, Patrick J. Boyle, (unknown), Michael J. Pugia, Subhash Basu	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact